Over two-thirds of biopharmaceutical manufacturers now report that their facility is experiencing capacity bottlenecks due to downstream processing. A number of factors continue to converge to create ...

Master of Biotechnology program (MBP) student Anita Huang looks back on her six-month internship at UCB in the United Kingdom and what she learned from the experience. In 2019, two students in ...

Downstream purification continues to pressure the biopharmaceutical manufacturing industry from a capacity standpoint, with recent increases in upstream yield and titers overcoming the relatively slow ...

Scaling bioprocesses from early development to GMP manufacturing is becoming more complex as biologics diversify and timelines compress. In this whitepaper, specialists share practical insights on how ...

Launching at the Festival of Biologics, ShunzymeX is designed to streamline process development and accelerate GMP readiness for complex biologics. TEESSIDE, England--(BUSINESS WIRE)--FUJIFILM ...

With the recent FDA approval of the CAR T-cell therapies Kymriah ® from Novartis and Yescarta ® from Kite Pharma, there has been a renewed interest in bioprocessing and the manufacturing facilities ...

Learn from the MHRA about evolving CMC expectations, submission criteria, and initiatives for streamlining approval routes for mRNA platforms. Continuous processing: Optimizing efficiency & ...